Contract facts
NONENo full NAICS 325412 intel page yet. Browse NAICS intelligence
NUCLEAR MEDICINE IMAGING PRODUCTS FOR MYOCARDIAL INFARCT IMAGING, DIAGNOSTIC IMAGING OF GALL BLADDER DISORDERS, AND BREAST CANCER NODULE IMAGING MEDICINE. is a federal NONE award for Defense Health Agency held by Sun Pharmaceutical Industries, Inc. Estimated value $1M ($967K obligated). Current period of performance ends Mar 10, 2027. Last award drew 3 bidders. Place of performance: BETHESDA MD.
NUCLEAR MEDICINE IMAGING PRODUCTS FOR MYOCARDIAL INFARCT IMAGING, DIAGNOSTIC IMAGING OF GALL BLADDER DISORDERS, AND BREAST CANCER NODULE IMAGING MEDICINE.
Recompete timing
PublicCurrent PoP ends Mar 10, 2027 (184 days remaining). Agencies typically plan 12–18 months ahead — at 6.0 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordSun Pharmaceutical Industries, Inc — $724K obligated across 7 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT001422P0039?
HT001422P0039 (Nuclear medicine imaging products for myocardial) is a Defense Health Agency award with a potential value of $1M, currently held by Sun Pharmaceutical Industries, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT0014-22-P-0039?
HT0014-22-P-0039 is the dashed form of PIID HT001422P0039 (Nuclear medicine imaging products for myocardial), held by Sun Pharmaceutical Industries, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT001422P0039?
Defense Health Agency awarded HT001422P0039 to Sun Pharmaceutical Industries, Inc (potential $1M).
Who is the incumbent on HT001422P0039?
Sun Pharmaceutical Industries, Inc is the incumbent with $724K across 7 related awards in SCOUT’s public footprint. The current period of performance ends Mar 10, 2027.
When does Sun Pharmaceutical Industries, Inc’s HT001422P0039 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 10, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Seen enough? Run one full capture cycle on HT001422P0039 — $90 for 90 days.
This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.
$1/day · one payment · no subscription
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.